Rein Therapeutics Inc Quick Ratio (RNTX) starting from the second quarter 2026 to second quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Rein Therapeutics Inc   (NASDAQ: RNTX)

Rein Therapeutics Inc 's Quick Ratio

RNTX's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Rein Therapeutics Inc 's Cash & cash equivalent grew by 881.48 % in the Q2 2026 sequentially, while Current Liabilities decreased, this led to improvement in Rein Therapeutics Inc 's Quick Ratio to 4.49, Quick Ratio remained below Rein Therapeutics Inc average.

Within Major Pharmaceutical Preparations industry 194 other companies have achieved higher Quick Ratio than Rein Therapeutics Inc in second quarter 2026. While Quick Ratio total ranking in the second quarter 2026 has deteriorated compared to the prior quarter from 2923 to 3049.

Explain Quick Ratio?
How much Cash & cash equivalents RNTX´s has?
What are RNTX´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

RNTX Quick Ratio (Jun 30 2026)
Q2		 (Mar 31 2026)
Q1		 (Dec 31 2025)
Q4		 (Sep 30 2025)
Q3		 (Jun 30 2025)
Q2
Y / Y Current Liabilities Change 26.19 % 128.16 % -14.49 % 1.5 % 55.84 %
Y / Y Cash & cash equivalent Change 662.44 % -40.16 % -75.01 % -77.07 % -73.89 %
Quick Ratio MRQ 4.49 0.33 0.65 0.7 0.74
RNTX's Total Ranking # 3049 # 2923 # 2671 # 2671 # 2109
Seq. Current Liabilities Change -28.8 % 177.4 % -14.42 % -25.34 % 28.73 %
Seq. Cash & cash equivalent Change 881.48 % 38.26 % -20.58 % -29.26 % -22.97 %



Quick Ratio second quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 195
Healthcare Sector # 326
Overall Market # 860


Quick Ratio Statistics
High Average Low
108.5 7.95 0.33
(Mar 31 2021)   (Mar 31 2026)




Financial Statements
Rein Therapeutics Inc 's Current Liabilities $ 10 Millions Visit RNTX's Balance sheet
Rein Therapeutics Inc 's Cash & cash equivalent $ 44 Millions Visit RNTX's Balance sheet
Source of RNTX's Sales Visit RNTX's Sales by Geography


Cumulative Rein Therapeutics Inc 's Quick Ratio

RNTX's Quick Ratio for the trailling 12 Months

RNTX Quick Ratio

 (Jun 30 2026)
12 Months		 (Mar 31 2026)
12 Months		 (Dec 31 2025)
12 Months		 (Sep 30 2025)
12 Months		 (Jun 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth 35.6 % 43.32 % 16.54 % 28.96 % 62.03 %
Y / Y Cash & cash equivalent TTM Growth 26.72 % -70.88 % -68.34 % -56.38 % -31.06 %
Quick Ratio TTM 1.63 0.54 0.84 1.19 1.74
Total Ranking TTM # 1944 # 1766 # 975 # 703 # 467
Seq. Current Liabilities TTM Growth 6.3 % 31.48 % -3.31 % 0.34 % 12.35 %
Seq. Cash & cash equivalent TTM Growth 217.47 % -14.61 % -32.1 % -31.15 % -27.05 %

Quick ratio ranking by company, industry and sector >> Back to RNTX Financial Strength Comparisons >> Go to Compare RNTX Quick Ratio to its Competitors

On the trailing twelve months basis RNTX Cash & cash equivalent more than doubled by 662.44 % in Q2 2026 year on year, faster than Current Liabilities, this led to increase in in Rein Therapeutics Inc 's Quick Ratio to 1.63, Quick Ratio remained below RNTX average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 432 other companies have achieved higher Quick Ratio than Rein Therapeutics Inc . While Quick Ratio overall ranking has improved so far to 0, from total ranking during the twelve months ending first quarter 2026 at 4051.

Explain Quick Ratio?
How much Cash & cash equivalents RNTX´s has?
What are RNTX´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 433
Healthcare Sector # 885
Within the Market # 3049


trailing twelve months Quick Ratio Statistics
High Average Low
5.59 2.54 0.52
(Sep 30 2021)   (Mar 31 2026)




Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry Quick RatioJun 30 2026 MRQ Cash & cash equivalentJun 30 2026 MRQ Current Liabilities
Vtv Therapeutics Inc   12.35 $ 86.643  Millions$ 7.017  Millions
Theravance Biopharma inc   12.30 $ 378.546  Millions$ 30.766  Millions
Coya Therapeutics Inc   12.29 $ 43.181  Millions$ 3.512  Millions
Bridgebio Oncology Therapeutics Inc   12.28 $ 634.167  Millions$ 51.634  Millions
Ocular Therapeutix Inc   12.17 $ 598.641  Millions$ 49.174  Millions
Wave Life Sciences Ltd   12.07 $ 613.194  Millions$ 50.815  Millions
Amylyx Pharmaceuticals Inc   11.86 $ 250.760  Millions$ 21.150  Millions
Moonlake Immunotherapeutics  11.83 $ 537.000  Millions$ 45.392  Millions
Eledon Pharmaceuticals Inc   11.77 $ 170.753  Millions$ 14.503  Millions
Tyra Biosciences Inc   11.76 $ 354.060  Millions$ 30.106  Millions
Opus Genetics Inc   11.69 $ 88.912  Millions$ 7.605  Millions
Aardvark Therapeutics Inc   11.57 $ 73.921  Millions$ 6.387  Millions
Dyne Therapeutics Inc   11.51 $ 898.475  Millions$ 78.029  Millions
Evommune Inc   11.50 $ 201.014  Millions$ 17.487  Millions
Bicara Therapeutics Inc   11.44 $ 497.259  Millions$ 43.475  Millions
Lipocine Inc   11.25 $ 23.267  Millions$ 2.068  Millions
Xenon Pharmaceuticals Inc   10.85 $ 930.686  Millions$ 85.795  Millions
Bicycle Therapeutics Plc  10.71 $ 510.052  Millions$ 47.635  Millions
Entrada Therapeutics Inc   10.44 $ 223.112  Millions$ 21.371  Millions
Vera Therapeutics Inc   10.33 $ 499.161  Millions$ 48.321  Millions
Ideaya Biosciences Inc   10.03 $ 828.955  Millions$ 82.677  Millions
Gri Bio Inc   9.95 $ 10.947  Millions$ 1.100  Millions
Renovorx Inc   9.86 $ 18.579  Millions$ 1.884  Millions
Savara Inc   9.83 $ 173.034  Millions$ 17.599  Millions
Bullfrog Ai Holdings Inc   9.79 $ 6.918  Millions$ 0.707  Millions
Enveric Biosciences Inc   9.63 $ 8.296  Millions$ 0.861  Millions
Pliant Therapeutics Inc   9.62 $ 158.500  Millions$ 16.484  Millions
Rezolute Inc   9.44 $ 107.801  Millions$ 11.418  Millions
Crescent Biopharma Inc   9.26 $ 171.593  Millions$ 18.537  Millions
Marker Therapeutics inc   9.10 $ 22.031  Millions$ 2.420  Millions

Date modified: 2026-08-16T08:56:59+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.